Compare Incyte Corporation (INCY) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Standard Lithium Ltd — how do they compare? Incyte Corporation trades at $120.63 (market cap $24.54B), while Standard Lithium Ltd trades at $2.42 (market cap $604.50M). The key difference: Incyte Corporation is far larger — about 40.6× Standard Lithium Ltd's market cap, and Incyte Corporation is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals.
| INCY | SLI | |
|---|---|---|
Market Cap | $24.54B | $604.50M |
Sector | Health | Basic Materials |
52-Week High | $129.93 | $5.65 |
52-Week Low | $81.61 | $1.93 |
Enterprise Value | $20.04B | $467.42M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Standard Lithium (SLI) trades at $2.41, down 4.74% on the day, with technical indicators showing a bullish trend despite recent price weakness. The company maintains strong analyst support with 100% buy ratings from 3 analysts, reflecting optimism about its South West Arkansas lithium project development. Recent earnings show improved performance with two consecutive quarterly beats, though the company remains unprofitable with negative ROE and ROA. Institutional interest is growing, with Amundi increasing its stake by 64.9% in Q1 2026 according to SEC filings.
The investment case centers on SLI's transition to production status with major project de-risking events, including a $225M DOE grant and construction contracts. However, significant execution risks remain as the company burns cash with negative operating cash flow. The path to profitability depends on successful project completion and lithium market conditions, creating both substantial upside potential and meaningful downside risk for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
